Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.6% – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s share price rose 6.6% on Friday . The company traded as high as $13.08 and last traded at $13.06. Approximately 99,123 shares traded hands during trading, a decline of 63% from the average daily volume of 267,281 shares. The stock had previously closed at $12.25.

Wall Street Analysts Forecast Growth

TYRA has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, January 13th. Finally, UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Price Performance

The stock’s 50 day moving average is $14.74 and its two-hundred day moving average is $18.44.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the sale, the director now owns 443,885 shares of the company’s stock, valued at $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 21,998 shares of company stock valued at $344,818 over the last quarter. 15.40% of the stock is owned by company insiders.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences during the fourth quarter worth about $31,000. US Bancorp DE bought a new stake in Tyra Biosciences during the fourth quarter worth about $50,000. Aquatic Capital Management LLC bought a new stake in Tyra Biosciences during the fourth quarter worth about $64,000. Wells Fargo & Company MN grew its stake in Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Tyra Biosciences by 130,587.5% during the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company’s stock worth $145,000 after buying an additional 10,447 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.